Immune checkpoint inhibitor-associated inclusion body myositis
https://doi.org/10.62546/3034-1477-2024-2-3-79-85
Abstract
Immune checkpoint inhibitor-associated myositis is an extremely rare adverse event. However, the high level of mortality, the possible combination with other fatal complications, myocarditis, and myasthenia gravis, serve as motivation for the active detection and treatment of myositis. The management of the patient should involve a neurologist and a rheumatologist. In most cases, the administration of glucocorticoids is effective. Nevertheless, there is currently insufficient data on the pathogenesis of myositis and the treatment algorithms for steroid-refractory variants. A clinical case of the development of inclusion-body myositis in a patient receiving combined immunotherapy with antiCTLA4 and anti-PD-1 agents is presented.
Keywords
immune checkpoint inhibitor-related myositis,
inclusion body myositis,
neurologic immune-related adverse events,
checkpoint inhibitors,
combined immunotherapy with CTLA4 and PD-1 inhibitors
Supporting agencies: The authors declare no conflict of interest.
About the Authors
A. S. Sarmatova
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Sarmatova Alexandra Sergeevna
56 Veteranov Ave., St. Petersburg 193318
R. V. Orlova
St. Petersburg State University; St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
7/9 Universitetskaya Emb., St. Petersburg 199034; 56 Veteranov Ave., St. Petersburg 193318
L. N. Lebedeva
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
56 Veteranov Ave., St. Petersburg 193318
S. V. Tarasenko
St. Petersburg City Clinical Oncology Dispensary
Russian Federation
Russian Federation
56 Veteranov Ave., St. Petersburg 193318
References
1. Litvinenko I.V., Zhivolupov S.A., Bardakov S.N. et al. Inflammatory myopathies: pathogenesis, clinical picture, diagnosis, treatment. Bulletin of the Russian Military Medical Academy, 2015, Vol. 3, No. 1, pp. 217–226 (In Russ.)
2. Wang D.Y., Salem J.E., Cohen J.V. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis // JAMA Oncol. 2018. Dec 1. Vol. 4, No. 12. Р. 1721–1728. doi: 10.1001/jamaoncol.2018.3923.
3. Allenbach Y., Anquetil C., Manouchehri A. et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities // Autoimmun Rev. 2020. Aug; Vol. 19, No. 8. Р. 102586. doi: 10.1016/j.autrev.2020.102586.
4. Kottschade L.A., Fazer-Posorske C., Schwecke A.J., Triple M syndrome: implications for hematology-oncology advanced practice providers // Clinical Journal of Oncology Nursing. 2023. Vol. 27, No. 5. Р. 463–467. https://doi.org/10.1188/23.CJON.463-467.
5. Yang H., Ding Z., An Z. et al. Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study // Expert Opinion on Drug Safety, 1–6. https://doi.org/10.1080/14740338.2024.2343023.
6. Pathak R., Katel A., Massarelli E. et al. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases // Oncologist. 2021 Dec. Vol. 26, No. 12. Р. 1052–1061. doi: 10.1002/onco.13931.
7. Palaskas N., Lopez‐Mattei J., Durand J.B. et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment // J. Am. Heart Assoc. 2020. Vol. 9. e013757.
8. Anquetil C., Salem J.E., Lebrun-Vignes B. et al. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution // Circulation. 2018 Aug 14. Vol. 138, No. 7. Р. 743–745. doi: 10.1161/CIRCULATIONAHA.118.035898.
9. Boutros A., Bottini A., Rossi G. et al. C. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature // ESMO Open. 2023. Feb. Vol. 8, No. 1. Р. 100791. doi: 10.1016/j.esmoop.2023.100791.
10. Longinow J, Zmaili M, Skoza W et al. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series // Cancer Med. 2023. Feb. Vol. 12, No. 3. Р. 2281–2289. doi: 10.1002/cam4.5050.
11. Shelly S., Triplett J., Pinto M. et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy // Brain Communications. 2020. Vol. 2, Issue 2, fcaa181, https://doi.org/10.1093/braincomms/fcaa181.
12. Guidon A.C., Burton L.B., Chwalisz B.K. et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors // Journal for ImmunoTherapy of Cancer. 2021. Vol. 9. e002890. doi: 10.1136/jitc-2021-002890.
13. Pinal-Fernandez I., Quintana A., Milisenda J.C. et al. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis // Ann. Rheum. Dis. 2023. Jun. Vol. 82, No. 6. Р. 829–836. doi: 10.1136/ard-2022-223792.
14. Protsenko S.A., Ballyuzek M.F., Vasiliev D.A. et al. Practical recommendations for the management of immune-mediated adverse events. Practical recommendations RUSSCO, part 2. Malignant tumors, 2023, Vol. 13, pp. 213–252 (In Russ.)
15. Haanen J., Obeid M., Spain L. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Ann. Oncol. 2022. Dec. Vol. 33, No. 12. Р. 1217–1238. doi: 10.1016/j.annonc.2022.10.001.
16. Thompson J.A., Hutchinson F., Schneider B. et al. Management of Immunotherapy-Related Toxicities NCCN Guidelines Version 1.2024 Available at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf (12/07/2023).
Review
For citations:
Sarmatova A.S., Orlova R.V., Lebedeva L.N., Tarasenko S.V. Immune checkpoint inhibitor-associated inclusion body myositis. Clinical Case in Oncology. 2024;2(3):79-85. (In Russ.) https://doi.org/10.62546/3034-1477-2024-2-3-79-85
Views:
109
Email this article 